Tapentadol in the treatment of tumor-related chronic pain

Tomasz Dzierżanowski; Aleksandra Ciałkowska-Rysz

eISSN: 2081-2833
ISSN: 2081-0016

Medycyna Paliatywna/Palliative Medicine

Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

4/2016
vol. 8

Send email

Copy url:

abstract:

Review paper

Tapentadol in the treatment of tumor-related chronic pain

Tomasz Dzierżanowski

,

Aleksandra Ciałkowska-Rysz

Medycyna Paliatywna 2016; 8(4): 157–163

Online publish date: 2017/03/07

View full text Get citation

Tapentadol is a novel analgesic of a dual mechanism of action, the first representative of the centrally acting analgesic drugs called MOR-NRI. It has the agonistic activity towards µ receptors (MOR) and non-opioid – inhibiting norepinephrine reuptake (NRI) at the spinal cord level. These two mechanisms unveil synergy, clinically confirmed in multiple kinds of nociceptive and neuropathic pain. In this paper, we described the place of tapentadol in the treatment of tumor-related pain, in comparison to other III step opioids of the analgesic ladder.

keywords:

Tapentadol in the treatment of tumor-related chronic pain

Tomasz Dzierżanowski , Aleksandra Ciałkowska-Rysz

tapentadol, chronic pain, cancer pain, opioids, Evidence Based Medicine

Tomasz Dzierżanowski

,

Aleksandra Ciałkowska-Rysz